Literature DB >> 2784607

Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid.

B M Uitdehaag1, W M Nillesen, O R Hommes.   

Abstract

Moderate doses of cyclophosphamide can cause effects on lymphocytes that may last for some time after discontinuation of the treatment. Since cyclophosphamide is also often used at high doses, we studied the short- and long-term effects of such a high dose (8 grams in 20 days) in 50 patients with chronic progressive multiple sclerosis with the use of monoclonal antibodies. The treatment caused a depletion of lymphocytes, especially CD4+ cells resulting in a significant decrease of the CD4/CD8 ratio. These changes can still be found up to 13.5 years after treatment. Although there was some recovery in the first few years after treatment this was only partial. Therefore, some of the effects of high dose cyclophosphamide on cellular immunity may be permanent. These changes should be taken into account when studying immune parameters or considering new treatments in these patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784607     DOI: 10.1111/j.1600-0404.1989.tb03702.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

3.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Authors:  Chitra Krishnan; Adam I Kaplin; Robert A Brodsky; Daniel B Drachman; Richard J Jones; Dzung L Pham; Nancy D Richert; Carlos A Pardo; David M Yousem; Edward Hammond; Megan Quigg; Carrilin Trecker; Justin C McArthur; Avindra Nath; Benjamin M Greenberg; Peter A Calabresi; Douglas A Kerr
Journal:  Arch Neurol       Date:  2008-06-09

5.  Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders.

Authors:  K Alonso; R Medenica
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

6.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

7.  Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.

Authors:  R D Medenica; S Mukerjee; K Alonso; G Lazovic; T Huschart
Journal:  J Clin Apher       Date:  1994       Impact factor: 2.821

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.